Cost-Effectiveness Analysis of Rivaroxaban in Secondary Prevention of ACS in Sweden
Nov 1, 2013, 00:00 AM
10.1016/j.jval.2013.08.1272
https://www.valueinhealthjournal.com/article/S1098-3015(13)03177-X/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1121
First Page :
A524
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03177-X&doi=10.1016/j.jval.2013.08.1272